FR3123357B1 - Aptamères ARN spécifiques de conformères de fibres de la protéine α-synucléine - Google Patents
Aptamères ARN spécifiques de conformères de fibres de la protéine α-synucléine Download PDFInfo
- Publication number
- FR3123357B1 FR3123357B1 FR2105529A FR2105529A FR3123357B1 FR 3123357 B1 FR3123357 B1 FR 3123357B1 FR 2105529 A FR2105529 A FR 2105529A FR 2105529 A FR2105529 A FR 2105529A FR 3123357 B1 FR3123357 B1 FR 3123357B1
- Authority
- FR
- France
- Prior art keywords
- seq
- conformers
- fiber
- syn
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000835 fiber Substances 0.000 title abstract 3
- 108091008103 RNA aptamers Proteins 0.000 title 1
- 102000003802 alpha-Synuclein Human genes 0.000 title 1
- 108090000185 alpha-Synuclein Proteins 0.000 title 1
- 108091023037 Aptamer Proteins 0.000 abstract 3
- 208000032859 Synucleinopathies Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 229920002477 rna polymer Polymers 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 238000011156 evaluation Methods 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
- 238000004393 prognosis Methods 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 238000013517 stratification Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/34—Allele or polymorphism specific uses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
La présente invention concerne un aptamère caractérisé en ce qu’il possède la capacité de distinguer les conformères de fibres d’α-Syn de type F de la protéine α-Syn (α-Syn) des conformères de fibres d’α-Syn de type R, et en ce qu’il comprend une séquence spécifique d’acide ribonucléique (ARN) modifié ayant au moins 85% d’identité avec une séquence choisie parmi SEQ ID NO :1, SEQ ID NO :2, SEQ ID NO :3, SEQ ID NO :4, SEQ ID NO :5, SEQ ID NO :6, et SEQ ID NO :7, de préférence choisie parmi SEQ ID NO :1 et SEQ ID NO :2. La présente invention concerne en outre une composition ou un kit comprenant au moins de ces aptamères, ainsi que leurs utilisations in vitro. La présente invention porte également sur une méthode de diagnostic de synucléinopathies ainsi qu’une méthode de stratification, de suivi, de pronostic et d’évaluation de l’efficacité d’un traitement d’une synucléinopathie, comprenant l’utilisation d’au moins un aptamère et/ou une composition et/ou un kit susmentionné.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR2105529A FR3123357B1 (fr) | 2021-05-27 | 2021-05-27 | Aptamères ARN spécifiques de conformères de fibres de la protéine α-synucléine |
US18/564,121 US20240240191A1 (en) | 2021-05-27 | 2022-05-25 | Rna aptamers specific for a-synuclein protein fiber conformers |
PCT/FR2022/050993 WO2022248805A1 (fr) | 2021-05-27 | 2022-05-25 | Aptameres arn specifiques de conformeres de fibres de la proteine a-synucleine |
EP22732601.4A EP4347838A1 (fr) | 2021-05-27 | 2022-05-25 | Aptameres arn specifiques de conformeres de fibres de la proteine a-synucleine |
JP2023572981A JP2024520044A (ja) | 2021-05-27 | 2022-05-25 | α-シヌクレインタンパク質繊維コンフォマーに特異的なRNAアプタマー |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR2105529A FR3123357B1 (fr) | 2021-05-27 | 2021-05-27 | Aptamères ARN spécifiques de conformères de fibres de la protéine α-synucléine |
FR2105529 | 2021-05-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
FR3123357A1 FR3123357A1 (fr) | 2022-12-02 |
FR3123357B1 true FR3123357B1 (fr) | 2024-04-12 |
Family
ID=76807799
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR2105529A Active FR3123357B1 (fr) | 2021-05-27 | 2021-05-27 | Aptamères ARN spécifiques de conformères de fibres de la protéine α-synucléine |
Country Status (5)
Country | Link |
---|---|
US (1) | US20240240191A1 (fr) |
EP (1) | EP4347838A1 (fr) |
JP (1) | JP2024520044A (fr) |
FR (1) | FR3123357B1 (fr) |
WO (1) | WO2022248805A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024172061A1 (fr) * | 2023-02-17 | 2024-08-22 | 国立大学法人京都大学 | Aptamère d'arn |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2657953A1 (fr) | 2005-07-19 | 2007-01-25 | University Of Rochester | Anticorps d'alpha-synucleine et techniques associees |
CA3079909A1 (fr) | 2017-10-23 | 2019-05-02 | Carleton University | Aptameres en tant qu'outil therapeutique pour prevenir l'agregation de proteines dans une maladie neurodegenerative |
-
2021
- 2021-05-27 FR FR2105529A patent/FR3123357B1/fr active Active
-
2022
- 2022-05-25 US US18/564,121 patent/US20240240191A1/en active Pending
- 2022-05-25 WO PCT/FR2022/050993 patent/WO2022248805A1/fr active Application Filing
- 2022-05-25 EP EP22732601.4A patent/EP4347838A1/fr active Pending
- 2022-05-25 JP JP2023572981A patent/JP2024520044A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP4347838A1 (fr) | 2024-04-10 |
FR3123357A1 (fr) | 2022-12-02 |
US20240240191A1 (en) | 2024-07-18 |
JP2024520044A (ja) | 2024-05-21 |
WO2022248805A1 (fr) | 2022-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lue et al. | TREM 2 Protein Expression Changes Correlate with A lzheimer's Disease Neurodegenerative Pathologies in Post‐Mortem Temporal Cortices | |
Vergeer et al. | Do labour market reforms reduce labour productivity growth? A panel data analysis of 20 OECD countries (1960–2004) | |
Simpson et al. | Population variation in oxidative stress and astrocyte DNA damage in relation to Alzheimer‐type pathology in the ageing brain | |
FR3123357B1 (fr) | Aptamères ARN spécifiques de conformères de fibres de la protéine α-synucléine | |
NZ625423A (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
KR20220015394A (ko) | 프라탁신 대체 요법의 유효성 결정을 위한 프라탁신 민감성 마커 | |
BR112022003663A2 (pt) | Método para tratar oftalmopatia tireoidiana (ted) em um indivíduo com ted; método para reduzir proptose em pelo menos 2 mm em um indivíduo com oftalmopatia tireoidiana (ted); método para tratar ou reduzir a gravidade de diplopia em um indivíduo com oftalmopatia tireoidiana (ted); método para tratar ou reduzir a gravidade de oftalmopatia tireoidiana (ted); método para reduzir proptose em um olho em um indivíduo com oftalmopatia tireoidiana (ted); método para reduzir pontuação de atividade clínica (cas) de oftalmopatia tireoidiana (ted); método para a) reduzir proptose em pelo menos 2 mm e b) reduzir a pontuação de atividade clínica (cas) em um indivíduo com oftalmopatia tireoidiana (ted); e método para melhorar a qualidade de vida em um indivíduo com oftalmopatia tireoidiana (ted) | |
MX2020013229A (es) | Endonucleasas cpf1 mutantes. | |
Yuan et al. | Interferon-stimulated gene 15 expression in systemic lupus erythematosus. | |
Rocha-Resende et al. | Immunomodulatory role of nonneuronal cholinergic signaling in myocardial injury | |
Tribouillard-Tanvier et al. | Role of cyclophilin A from brains of prion-infected mice in stimulation of cytokine release by microglia and astroglia in vitro | |
MA38638A1 (fr) | Marqueurs pour troubles liés à la sphingomyélinase acide et leurs utilisations | |
WO2011103330A3 (fr) | Nouvelle phosphorylation de la troponine cardiaque i utilisée comme un moniteur de lésion cardiaque | |
EA202092612A1 (ru) | Способ ферментативного дегуммирования масла | |
Wood et al. | FKRP-dependent glycosylation of fibronectin regulates muscle pathology in muscular dystrophy | |
Wang et al. | Long non‐coding RNA XIST alleviates sepsis‐induced acute kidney injury through inhibiting inflammation and cell apoptosis via regulating miR‐155‐5p/WWC1 axis | |
Meeus et al. | Unravelling intracellular immune dysfunctions in chronic fatigue syndrome: interactions between protein kinase R activity, RNase L cleavage and elastase activity, and their clinical relevance | |
Klein et al. | Influence of the angiotensin converting enzyme inhibitor ramipril on high-sensitivity C-reactive protein (hs-CRP) in patients with documented atherosclerosis | |
Casal et al. | Serum markers of monocyte/macrophage activation in patients with Alzheimer's disease and other types of dementia | |
Said et al. | Protein-synthesizing function and functional state of the liver of dogs at experimental toxocariasis | |
O'Rourke et al. | Predicting beta-interferon failure in relapsing-remitting multiple sclerosis | |
JP2019500053A (ja) | 代謝性疾患におけるマイクロrna | |
Gajofatto et al. | Clinical and biomarker assessment of demyelinating events suggesting multiple sclerosis | |
MXPA05009251A (es) | Composiciones y metodos para diagnosticar y tratar asma u otras enfermedades alergicas o inflamatorias. | |
Bonsignore et al. | Mortality in Alzheimer’s disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PLFP | Fee payment |
Year of fee payment: 2 |
|
PLSC | Publication of the preliminary search report |
Effective date: 20221202 |
|
PLFP | Fee payment |
Year of fee payment: 3 |
|
PLFP | Fee payment |
Year of fee payment: 4 |